kidney disease glp 1 GLP-1s and Disease​: Benefits and Risks to Consider Glucagon-Like Peptide-1 Receptor Agonist Use

Broad support for basic science is necessary to bring about the next generation of interventions

There are currently no GLP-1 medications that can be absorbed through the skin, says C

The Physician Summary Report makes that hand-off possible

Companies are racing to develop alternatives to injectable diabetes and weight loss drugs Injectable peptide drugs targeting the glucagon-like peptide 1 (GLP-1) receptor have had massive impact on approaches to treating diabetes and obesity, bringing huge revenue boosts to makers Novo Nordisk and Eli Lilly

The fluorescence was measured in an EnVision plate reader (PerkinElmer), and cAMP levels are expressed as a ratio of 665/620 nm